Alvotech Marks Denosumab Milestone

AVT03 Proposed Biosimilar To Prolia/Xgeva Passes PK Study; Further Trials Ongoing

 
• By Dave Wallace

Alvotech has reported the latest clinical trial results for its AVT03 proposed denosumab biosimilar rival to Prolia and Xgeva.

Alvotech’s AVT03 denosumab candidate has passed a PK study

More from Biosimilars

More from Products